Author Archives: Warren Woessner

The Solicitor’s Holistic Approach to the Mayo/Alice Analysis in American Axle

This is not exactly breaking news, and other commentators have discussed it, but I think that the Solicitor General’s Amicus Brief urging the Supreme Court to grant cert. in American Axle v. Neapco Holdings, Appeal No. 20-891 (May 2022) contains … Continue reading

Posted in Patent Eligible Subject Matter | Tagged | Leave a comment

Almirall v. Amneal Pharmaceuticals – Negative Limitations II

This post gets a “Part II” designation because the Fed. Cir. clarified the support necessary to find a negative limitation in the prior art (Almirall LLC v. Amneal Pharmaceuticals LLC, Appeal No. 2020-2331 (Fed. Cir., March 14, 2022)). In my … Continue reading

Posted in Obviousness, Prior Art | Tagged , | Leave a comment

Qualcomm v. Apple – Pyrrhic Victory for Qualcomm?

So far, it’s been a slow year for jurisprudence in the life sciences, so I thought I would take a look at the somewhat quirky decision in Qualcomm, Inc. v. Apple, Inc., Appeal nos. 2020-1558, -1559 (Fed. Cir., February 1, … Continue reading

Posted in Prior Art | Tagged , , | Leave a comment

Novartis v. Accord – No Limits on Negative Limitations?

A split panel of Judges O’Malley, Linn and Moore (dissenting) affirmed a district court ruling that the claims of U.S. Pat. No. 9,187,405 met the written description requirement (WDR) of s. 112(a). Novartis Pharmaceuticals v. Accord Healthcare Inc., Appeal No. … Continue reading

Posted in Written Description Requirements (WDR) | Tagged , | Leave a comment